This panel will discuss two out licensing deals with different emphases and outcomes. We will focus on the management strategies of big Pharma and venture investors. We will attempt to highlight the emphasis different investors place on investment criteria.

• To present thought processes and perspectives from Big Pharma, biotech and VCs about out licensing and different out licensing strategies
• To better understand how assets available for out-licensing are identified and extracted from large partners and what management structures are optimal, based on two real-life examples
• To better understand advantages/disadvantages of (a) financing out-licensed products with new investors and (b) subsequent business development initiatives with these out-licensing products with prospective partners